UCB has announced the top line results from a phase 2b study of olokizumab in adult patients who suffer from rheumatoid arthritis (RA).
The aim of this work is to review the efficacy of various doses, analysing the frequencies of olokizumab relative to placebo.
The research met its primary endpoint of illustrating a significant reduction in the disease activity score at week 12 through all olokizumab dose groups relative to placebo, with all of them showing a significant improvement in disease activity score.
As well as this, the research indicated that olokizumab and tocilizumab both showed comparable efficacy, measured by the drug analysis service scores in the population.
Olokizumab was well tolerated through all doses and showed a safety profile comparable to tocilizumab and consistent with known effects of IL-6 inhibitors.
Ismail Kola, president of UCB New Medicines, UCB’s research and early development division, said: "UCB is committed to developing new therapies offering breakthrough innovation to people living with severe diseases.
"We are very satisfied that the first results for the primary endpoint confirm our data models. However, our current data do not suggest sufficient differentiation potential versus the active comparator."
Mr Kola went on to say that the company is now exploring appropriate options for olokizumab, including partnering.
He added that the company is striving to allocate its funds and resources to promising late and early pipeline projects in the fields of immunology and neurology.
The study lasted three months and was a randomised, double-blind, placebo-controlled, close ranging piece of research, with around 220 patients with moderately-to severely-active RA taking part.
Recently, UCB introduced its Neupro solution in the US, which hopes to treat Parkinson's Disease and Restless Legs Syndrome.
The patch hopes to improve the motor function and activity of daily living among PD patients.
Over 100,000 people have already been treated with the drug, with research showing that it offers efficacy, tolerability and safety.
CSL are a niche recruitment agency with a variety of Drug Safety Jobs available.